Mutational Testing

Blueprint Medicines Presents Cost of Testing Poster

Blueprint Medicines presented a poster titled “The Cost Impact of Increased Molecular Testing Rates for the Treatment of Patients with Gastrointestinal Stromal Tumors” at the annual meeting of the AMCP.

By |2020-04-30T14:50:52-04:00April 30th, 2020|Mutational Testing, News, Patient Support|

LRG Assisted in CAP Guidelines Modifications with a Diagnostic Algorithm

The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.

By |2019-08-29T10:18:35-04:00August 29th, 2019|Advocacy, Mutational Testing, News|

LRG Webcast: Genetic Testing and SDHx Mutations

Genetic Testing and SDHx Mutations: What do they have to do with PGL/GIST/Pheos? This webcast highlights how SDHx mutations impact risks for paraganglioma, pheochromocytomas, and GIST, why genetic testing is helpful for any diagnosis [...]

By |2020-07-09T16:27:33-04:00May 7th, 2019|GIST Education, Mutational Testing, Webcast|

LRG Webcast: GI Stromal Tumors: A PatholoGIST’s Point of View

GI Stromal Tumors: A PatholoGIST's Point of View Mutational Testing in GIST Mutational Testing in GIST is a vital component for survival, especially as cancer treatment becomes more individualized. In this webcast, Dr. Chris [...]

By |2020-07-09T16:44:24-04:00April 23rd, 2019|GIST Education, Mutational Testing, Webcast|

Life Fest 2018: Role of Mutational Analysis and Next Generation Sequencing in GIST

Role of Mutational Analysis and Next Generation Sequencing in GIST Andrew Rosenberg, MD, Sylvester Comprehensive Cancer Center View all Life Fest 2018 Videos

By |2019-09-16T15:30:09-04:00September 18th, 2018|Events, Mutational Testing, Video|

New Technology Developed Which Can Predict GIST Patient’s Response to Drugs with Amazing Accuracy

Researchers have developed a test that can accurately identify over 20% of GIST patients that are unlikely to respond to currently approved treatments. In addition, it can identify which patients need a higher dose [...]

By |2019-07-03T10:48:28-04:00June 29th, 2018|GIST Education, Mutational Testing, News, Newsletter|
Go to Top